Welcome to our dedicated page for Clorox Co Del SEC filings (Ticker: CLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clorox Company (NYSE: CLX) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations as a consumer products manufacturer in the polish and other sanitation good manufacturing industry. This SEC filings page aggregates those disclosures and pairs them with AI-powered summaries to help readers interpret the information more efficiently.
Key filings for CLX include annual reports on Form 10-K, which typically describe the company’s business segments—Health and Wellness, Household, Lifestyle and International—along with risk factors, discussion of strategy and detailed financial statements. Quarterly reports on Form 10-Q update investors on interim performance, including segment results, margin drivers, cash flow and the impact of initiatives such as the U.S. enterprise resource planning (ERP) transition and portfolio changes like the divestiture of the Better Health Vitamins, Minerals and Supplements business.
Clorox also uses current reports on Form 8-K to disclose material events. Recent 8-K filings have covered quarterly and annual financial results, supplemental financial information, and matters submitted to a shareholder vote at the annual meeting, including director elections, advisory votes on executive compensation and ratification of the independent registered public accounting firm. Other 8-Ks may address leadership changes or other significant corporate developments.
The company’s proxy statement on Form DEF 14A provides additional detail on governance, board composition, executive compensation, strategic priorities such as the IGNITE strategy and oversight of areas like risk management and sustainability. For those interested in ownership and compensation, this document is a primary source.
On this page, filings are updated as they are released to EDGAR. AI-generated highlights and plain-language explanations help clarify complex topics such as non-GAAP measures (for example, organic sales growth, adjusted EBIT and adjusted EPS), the effects of the ERP transition on reported results, and the rationale behind portfolio actions. Users can also review any available insider-related disclosures, such as Form 4 filings, to see reported transactions by directors and officers.
Whether you are analyzing Clorox’s segment performance, reviewing governance practices, or tracking shareholder votes and executive compensation, this filings hub offers structured access to the company’s regulatory record with tools designed to make lengthy documents more approachable.
The Clorox Company (CLX) reported Q1 FY26 results with lower sales and earnings. Net sales were $1,429 million, down 19% year over year, as shipments normalized after ERP-related pull-forward in Q4 FY25. Gross profit was $596 million and gross margin declined to 41.7% from 45.8%, reflecting lower volume and higher manufacturing and logistics costs, partly offset by savings. Diluted EPS was $0.65 versus $0.80.
Operating cash flow was $93 million (vs. $221 million), driven by lower cash earnings and inventory, offset by lower receivables and higher payables. Current liabilities exceeded current assets by $539 million, primarily due to the upcoming cash purchase of P&G’s 20% Glad venture interest; the estimated fair value of that interest was $476 million, with $488 million recognized in accounts payable and accrued liabilities. Clorox cites expected operating cash flow, strong credit ratings, and available borrowing capacity to fund needs; its $1,200 million revolver was undrawn.
By segment, net sales declined: Health & Wellness $565 million (-19%), Household $362 million (-19%), Lifestyle $245 million (-23%), and International $253 million (-2%). The effective tax rate was 23.4% (vs. 41.8%). Dividends declared were $2.48 per share; share repurchases totaled $129 million.
The Clorox Company announced executive leadership changes. Eric Reynolds, Executive Vice President – Chief Operating and Strategy Officer, provided notice of his intention to resign after 27 years with the company. He will step down from his role effective December 2, 2025.
Reynolds will be available on an advisory basis as needed through February 2, 2026. The company stated it does not expect to appoint a replacement for Mr. Reynolds.
Insider transaction summary for CLOROX CO (CLX)
On
Laurene E. Peck, Vice President, Chief Accounting Officer & Corporate Controller of Clorox Co (CLX), reported changes in her beneficial ownership on
Insider stock settlement and tax withholdings recorded for CLOROX (CLX). On
Clorox (CLX) director and EVP Stacey Grier reported transactions dated
Executive stock vesting and tax-related share withholdings: The Chief Operating Officer reported transactions on
Insider transaction summary: An executive officer of Clorox Co. (CLX) reported transactions on
Insider transactions at Clorox Co (CLX): an executive reported multiple equity transactions on
FAQ
What is the current stock price of Clorox Co Del (CLX)?
What is the market cap of Clorox Co Del (CLX)?
